64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1869-1875

  Tamura, Kenji ^a   Kurihara, Hiroaki ^a   Yonemori, Kan ^a   Tsuda, Hitoshi ^a   Suzuki, Junko ^a   Kono, Yuzuru ^a   Honda, Natsuki ^a   Kodaira, Makoto ^a   Yamamoto, Harukaze ^a   Yunokawa, Mayu ^a   Shimizu, Chikako ^a   Hasegawa, Koki ^b   Kanayama, Yousuke ^b   Nozaki, Satoshi ^b   Kinoshita, Takayuki ^a   Wada, Yasuhiro ^b   Tazawa, Shusaku ^b   Takahashi, Kazuhiro ^b   Watanabe, Yasuyoshi ^b   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b RIKEN   (Japan)

Author keywords

HER2 positive breast cancer; Molecular imaging; PET; Trastuzumab

Indexed keywords

COPPER TETRAXETAN TRASTUZUMAB CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOISOTOPE; UNCLASSIFIED DRUG; 64CU DOTA TRASTUZUMAB; 64CU-DOTA-TRASTUZUMAB; COPPER 64; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; HUMAN; ISOTOPE LABELING; MIDDLE AGED; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOACTIVITY; URINALYSIS; BREAST TUMOR; FEASIBILITY STUDY; HER2-POSITIVE BREAST CANCER; IMAGE PROCESSING; METABOLISM; METASTASIS; METHODOLOGY; MOLECULAR IMAGING; PATHOLOGY; PET; SAFETY; SCINTISCANNING; DIAGNOSTIC USE;

64CU; HER2-POSITIVE BREAST CANCER; MOLECULAR IMAGING; PET; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEASIBILITY STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; SAFETY;

EID: 84891686968     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118612     Document Type: Article

References (30)

1. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
5. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063-1070.
6. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
7. Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol. 2010;28:3264-3270.
8. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol. 2011;22:1547-1553.
9. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artifact? Insights through meta-analysis. Breast Cancer Res Treat. 2011; 129:659-674.
10. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
11. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
12. Baselga J, Cortés J, Kim SB, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366:109-119.
13. Verma S, Miles D, Gianni L, et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
14. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051.
15. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
16. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471-1478.
17. Reddy S, Shaller CC, Doss M, et al. Evaluation of anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011;17:1509-1520.
18. 89Zr- trastuzumab PET visualises HER2 down regulation by the HSP90 inhibitor NVP-AUY922 in a human tumor xenograft. Eur J Cancer. 2010;46:678-684.
19. Börjesson PK, Jauw YW, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
20. 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
21. 111In CHX-A" DTPA trastuzumab in solid tumors using gamma-camera imaging [abstract]. J Nucl Med. 2011;52(suppl 1):308P.
22. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenetic antibodies. J Natl Cancer Inst. 2002;94:1484-1493.
23. 64Ci-labeled linear peptide antagonist by microPET. Clin Cancer Res. 2008;14:4758-4766.
24. Obata A, Kasamatsu S, McCarthy DW, et al. Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron. Nucl Med Biol. 2003;30:535-539.
25. Iijima M, Kadoya H, Hatahira S, et al. Nanocapsules incorporating IgG Fcbinding domain derived from Staphylococcus aureus protein-A for displaying IgGs on immunosensor chips. Biomaterials. 2011;32:1455-1464.
26. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
27. 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
28. 64Ci-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3′. Molecular Imaging and Contrast Agent Database (MICAD). http://www.ncbi.nlm.nih.gov/ books/NBK99555/. Published May 3, 2013. Updated August 9, 2013. Accessed August 29, 2013.
29. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17:6437-6447.
30. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet. 2010;376:687-697.